ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: admabiologics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/19/2023 | $5.00 | Strong Buy | Raymond James |
10/13/2022 | $5.00 | Buy | Mizuho |
11/11/2021 | $5.00 | Outperform → Strong Buy | Raymond James |
11/9/2021 | $4.50 | Overweight | Cantor Fitzgerald |
10/26/2021 | $6.00 → $5.00 | Outperform | Raymond James |
8/12/2021 | $7.00 → $6.00 | Buy | HC Wainwright & Co. |
7/6/2021 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
ARS - ADMA BIOLOGICS, INC. (0001368514) (Filer)
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement C-code, C9072, for ASCENIV which is effective January 1, 2021. “Assignment of this new C-code by CMS for ASCENIV, along with pass-through payment status, will provide a more streamlined reimbursement process in the increasingly important hospital outpatient setting,” said Adam Grossman,
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA's Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue Guidance Increased to More Than $400 Million and $445 Million, Respectively FY 2024 GAAP Net Income Guidance Increased to More Than $105 Million and Adjusted EBITDA Guidance Increased to More Than $150 Million FY 2025 GAAP Net Income Guidance Increased to More than $155 Million and
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN.
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- A
RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN.
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net Income of $0.7 Million FY 2024 and 2025 Total Revenue Guidance Increased to More Than $330 Million and $380 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $65 Million and Adjusted EBITDA Guidance Increased to More Than $90 Million FY 2025 Net Income Guidance Increased to More than $115 Million and Adjusted EBITDA Guidance Increased to More Than $140 Million Innovative Growth Opportunities Targeting Manu
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2023 financial results on February 28, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants may register for the call here to receive the dial-in numbers and
3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to $74.2 Million 3Q2023 Adjusted EBITDA(1) Grew to $12.7 Million, a 98% Q-o-Q Increase FY2023 Total Revenue Now Expected to Exceed $250 Million, Increased from $240 Million Adjusted EBITDA and Net Income Growth Expected Over the Remainder of 2023 and Beyond FY2024 and 2025 Total Revenue Guidance Increased to More than $290 Million and $335 Million, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08,
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants may register for the call here to receive the dial-in numbers and unique
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicate
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, participants may register for the call here to receive the dial-in numbers and unique PIN to access the
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00
Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00
Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of ADMA Biologics with a rating of Overweight and set a new price target of $4.50
Raymond James reiterated coverage of ADMA Biologics with a rating of Outperform and set a new price target of $5.00 from $6.00 previously
HC Wainwright & Co. reiterated coverage of ADMA Biologics with a rating of Buy and set a new price target of $6.00 from $7.00 previously
HC Wainwright & Co. reiterated coverage of ADMA Biologics with a rating of Buy and set a new price target of $7.00 from $10.00 previously
Raymond James reiterated coverage of ADMA Biologics with a rating of Outperform and set a new price target of $6.00 from $7.00 previously
Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers ADMA's Total Debt to $105 Million, a 22% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced it has repaid $30 million from its original $72.5 million revolving credit facility with Ares Capital. Following the partial paydown, ADMA has reduced its total gross debt to $105 million, comprised of its e
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA's Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue Guidance Increased to More Than $400 Million and $445 Million, Respectively FY 2024 GAAP Net Income Guidance Increased to More Than $105 Million and Adjusted EBITDA Guidance Increased to More Than $150 Million FY 2025 GAAP Net Income Guidance Increased to More than $155 Million and
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN.
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- A
RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN.
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM Provides for Improved Inventory Management and Ease of Product Administration to Patients Approval of Extended Ambient Storage Conditions for ASCENIV & BIVIGAM is Immediately Effective and Now Commercially Available to U.S. Healthcare Providers RAMSEY, N.J. and BOCA RATON, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manuf
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET. A live audio webcast of the call will be available under "Events & Webcasts" in the investor section of the Company's website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company's website appr
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters will be transitioning from these positions to a consulting role, effective April 1, 2024. "On behalf of ADMA's Board of Directors and myself, we extend our sincere gratitude to Brian for all of his contributions to ADMA, from working with me in taking the Company public over a decade ago, to being an integral team member
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net Income of $0.7 Million FY 2024 and 2025 Total Revenue Guidance Increased to More Than $330 Million and $380 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $65 Million and Adjusted EBITDA Guidance Increased to More Than $90 Million FY 2025 Net Income Guidance Increased to More than $115 Million and Adjusted EBITDA Guidance Increased to More Than $140 Million Innovative Growth Opportunities Targeting Manu
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2023 financial results on February 28, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants may register for the call here to receive the dial-in numbers and
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
3 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Salesforce, Inc. (NYSE:CRM) has been a huge winner and recommended holding the stock. “It does have trouble getting traction,” he added. Salesforce reportedly cut around 300 roles to streamline operations, highlighting the tech industry's ongoing focus on cost control. ADMA Biologics, Inc. (NASDAQ:ADMA) has been a rocket, Cramer said. “If I were you, I would take some off the table.” On May 9, ADMA Biologics reported better-than-expected first-quarter financial results and issued strong FY24 and FY25 revenue guidance. When asked about Ouster, Inc. (NYSE:OUST), he said, “I would actually take some off the table. It's another p
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Thursday. Shares of Leslie’s, Inc. (NASDAQ:LESL) fell sharply in today's pre-market trading after the company issued preliminary third-quarter financial results below estimates and cut its FY24 guidance. After the market close on Wednesday, Leslie's announced it now expects third-quarter revenue of approximately $570 million versus estimates of $615.407 million. The pool supply company anticipates third-quarter adjusted earnings of 32 cents to 33 cents per share versus Benzinga Pro estimates of 42 cents per share. Leslie's also cut its full-year 2024 revenue guidance from a range of $1.14
ADMA Biologics's (NYSE:ADMA) short percent of float has fallen 23.1% since its last report. The company recently reported that it has 7.27 million shares sold short, which is 3.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
In the latest quarter, 6 analysts provided ratings for ADMA Biologics (NASDAQ:ADMA), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $11.83, accompanied by a high estimate of $15.00 and a low estimate of $10.00. Witnessing a positive shift, the cur
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price target from $10 to $15.
6 analysts have shared their evaluations of ADMA Biologics (NASDAQ:ADMA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 1 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.58, along with a high estimate of $14.00 and a low estimate of $7.50. This upw
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $12 to $14.
Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Strong Buy and raises the price target from $8 to $10.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price target from $8 to $10.